SOURCE: Micromet Inc.

January 29, 2007 03:00 ET

Micromet Reports on First International Symposium on EpCAM Biology and Clinical Application

CARLSBAD, CA -- (MARKET WIRE) -- January 29, 2007 --

Meeting review published in British Journal of Cancer supports EpCAM (CD326) as prime target for cancer therapy

Carlsbad, CA, January 29, 2007 - Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases, reports in the British Journal of Cancer (1) on proceedings from an international symposium on EpCAM, a target antigen the company has selected for two drug candidates. One is the human antibody adecatumumab (MT201), which has completed two phase 2a trials. The other one is MT110, a BiTE® molecule, which is in formal preclinical development. EpCAM is one of the most frequently and intensely expressed tumor-associated antigens known.

One highlight of the symposium was very recent data from the laboratory of Olivier Gires, University of Munich, showing that overexpressed EpCAM is a highly potent oncogenic signaling molecule in cancer cells. Components of a signal transduction pathway have been deciphered that link overexpressed EpCAM on cancer cells to the induction of the proto-oncogene c-myc in the cell nucleus. Other investigators showed that EpCAM on normal epithelial cells are tightly associated with other proteins in the cell membrane. Such complexes may shield particular antibody binding sites on EpCAM of normal cells, which may contribute to the therapeutic window of certain anti-EpCAM antibodies. A comprehensive overview on ongoing clinical and pre-clinical studies was provided covering a variety of therapeutic approaches targeting EpCAM.

"This was the first symposium on EpCAM after its discovery 30 years ago" commented Patrick Baeuerle, CSO of Micromet, Inc. and co-author of the meeting review. "We are very excited about the most recent revelations on the role of EpCAM as a signaling molecule in cancer and about new data confirming EpCAM's negative prognostic potential in certain cancer types. Clinical progress with several therapies targeting EpCAM should finally validate EpCAM as a broadly applicable target for pan-carcinoma therapy." ###

Reference (1) Baeuerle, P.A. et Gires, O., EpCAM (CD326) - finding its role in cancer, Brit. J. Cancer, published online ahead of print (2007)

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company focusing on the development of novel, proprietary antibody-based products for cancer, inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. Adecatumumab (MT201) is a recombinant human monoclonal antibody which targets EpCAM expressing tumors with which Micromet has completed two phase 2a clinical trials, one in patients with breast cancer and the other in patients with prostate cancer. In addition, a phase 1b trial evaluating the safety and tolerability of MT201 in combination with docetaxel is currently ongoing in patients with metastatic breast cancer. MT103 (MEDI-538), which is the first product candidate based on the novel BiTE® product development platform, is being evaluated in a phase 1 clinical trial for the treatment of patients with non-Hodgkins lymphoma in conjunction with MedImmune. The BiTE® product development platform is based on a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. Micromet has established collaborations with MedImmune and Serono.

More information:

Contact Information:

Investor Contact:
Ines-Regina Buth
+1 760 494 4235 (US)
+49 (0)30 2363 2768 (Europe)

Media Contacts:
Europe: Evelyn Wolf
+49 (0)89 4445 2099

US: Susan Noonan
(212) 966 3650

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the efficacy, safety, and intended utilization of Micromet's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research, discovery and clinical trials of new product candidates, and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that we will not obtain approval to market our products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for future revenues under the terms of our existing collaboration agreements. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed in our periodic reports and other filings with the SEC, including the "Risk Factors" sections of such reports.

Any forward-looking statements are made pursuant to Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and, as such, speak only as of the date made. Micromet undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information